Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash
Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due ...
Ophthalmology Times13d
Cognition Therapeutics publishes research on the potential of zervimesine (CT1812) for treating dry AMD
Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
Ophthalmology Times6d
A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey
Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...
Business Wire10d
Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills ...
Each patient received a 50,000-cell suspension of RPESC-RPE-4W implanted under the macula ... of adults affected by dry AMD and geographic atrophy. We look forward to advancing our Phase 1/2a ...
Seeking Alpha6d
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript
As most of you know, our lead candidate OpRegen for patients with dry AMD with geographic atrophy is an allogeneic cell transplant comprised of RPE cells. OpRegen is delivered as a suspension to ...
Mena FN18d
Cognition Therapeutics Publishes Research Supporting The Potential Of Zervimesine In Dry AMD
From this, we found that treatment with zervimesine altered proteins and pathways strongly associated with geographic atrophy and macular degeneration ... “Retinal pigment epithelial (RPE) cells are ...
pharmaphorum4d
Complement raises €72m for geographic atrophy gene therapy
The phase 1b trial will enrol patients with geographic atrophy secondary to age-related ... of photoreceptors and retinal pigment epithelial (RPE) cells in the central portion of the retina ...
Cognition Therapeutics, Inc.: Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the "Company" or "Cognition") ...
Medscape20d
Optical Coherence Tomography and Fundus Autofluorescence Imaging in Uveitis
Serpiginous chorioretinopathy is a rare form of posterior uveitis that causes inflammation and subsequent atrophy of the choroid, RPE and retina. The disease typically starts near the optic nerve ...
Nasdaq17d
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
From this, we found that treatment with zervimesine altered proteins and pathways strongly associated with geographic atrophy and macular ... pigment epithelial (RPE) cells are responsible for ...
pharmaphorum5d
Apellis breaks new ground in geographic atrophy
Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight ... and retinal pigment epithelial (RPE) cells, the central portion of ...